-
Product Insights
NewNet Present Value Model: Erasca Inc’s ERAS-007
Empower your strategies with our Net Present Value Model: Erasca Inc's ERAS-007 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Pancreatic Cancer Drug Details: ERAS-601 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Gastric Cancer Drug Details: ERAS-601 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Non-Small Cell Lung Cancer Drug Details: ERAS-601 is...
-
Product Insights
Net Present Value Model: Erasca Inc’s ERAS-601
Empower your strategies with our Net Present Value Model: Erasca Inc's ERAS-601 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Next Era Blythe Solar Park
Next Era Blythe Solar Park is a solar PV project located in California, United States. The project is owned and developed by NextEra Energy Resources LLC. The project came online in 2016. Empower your strategies with our Next Era Blythe Solar Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
New Era Enviro Solar PV Park
New Era Enviro Solar PV Park is a solar PV project located in Andhra Pradesh, India. The project is owned by Greenko Energies Pvt Ltd and was developed by New Era Enviro Ventures (Mahbubnagar) Pvt Ltd. The project came online in 2016. Empower your strategies with our New Era Enviro Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to...
-
Analyst Opinions
Ghost Kitchens in the Post-Pandemic Era – Trend Analysis
Ghost Kitchens in the Post-Pandemic Era Report Overview The pandemic encouraged brands to explore delivery-only concepts such as ghost kitchens. A kitchen setup wherein a single restaurant prepares various cuisines or multiple virtual restaurants share a kitchen is known as ghost kitchen. Dine-in channel continues to have the largest market share in the food service sector. However, the demand for home deliveries has increased significantly as well. Food service providers need to understand key markets for takeaway channel growth to...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ERAS-601 in Solid Tumor Drug Details:ERAS-601 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ERAS-601 in Metastatic Colorectal Cancer Drug Details:ERAS-601 is under development for the...